HER-2 NEGATIVE BREAST CANCER MARKET ANALYSIS

Market Challenges And Opportunities

Global HER-2 Negative Breast Cancer Market Drivers:

Growing burden of breast cancer to augment market growth

One of the key factors expected to augment the growth of the global HER-2 negative breast cancer market over the forecast period is the rise in burden of breast cancer across the globe. For instance, according to the American Cancer Society, more than 15% to 20% of breast tumors have higher levels of the protein known as HER2. These cancer are called HER2-positive breast cancer. Most breast cancers are HER2-negative. Cancer that may be HER2 negative are breast, bladder, ovarian, pancreatic, and stomach cancer. According to the National Cancer Institute (NCI), around 78% of breast cancers are HER2-negative and don’t produce too much HER2.

Rise in number of clinical trials to underpin market growth

Another factor which is driving the growth of the global HER-2 negative breast cancer market is the rise in number of clinical trials. For instance, with the increase in burden of breast cancer, the number of clinical trials is also increasing with the rapid pace. According to the ClinicalTrials.gov, March 2022 report, ZB716 is in phase II development as monotherapy and in combination with palbociclib in patients with HER2-negative locally advanced or metastatic breast cancer. For the people with HER-2 negative breast cancer, blockage of the ER pathway has been proven to be an effective anticancer approach. This in turn is driving the market growth.

Global HER-2 Negative Breast Cancer Market Opportunities:

Rise in demand for safe & effective treatment is expected to offer significant growth opportunities for players in the global HER-2 negative breast cancer market. For instance, with the increase in awareness among people about HER-2 negative breast cancer, demand for safe, effective treatment is also increasing rapidly. In December 2022, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended approval for the use of Enhertu (fam-trastuzumab deruxtecan-nxki) monotherapy for adults with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting.

Rise in focus on the development of novel drugs or therapies is expected to offer lucrative growth opportunities for players in the global HER-2 negative breast cancer market. For instance, players in the market are focusing on developing or launching novel drugs or therapies in the market to meet increasing demand. In October 2021, the U.S. Food & Drug Administration (FDA) approved abemaciclib (Verzenio) in combination with endocrine therapy for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative breast cancer at high risk of recurrence and a Ki-67 score ≥20%, as determined by an FDA approved test.

Global HER-2 Negative Breast Cancer Market Restraints:

High cost of treatment to hinder growth of the market

One of the key factors expected to hamper the growth of the global HER-2 negative breast cancer market is the high cost of treatment. According to the National Cancer Institute (NCI), per patient cost was US$ 292,155 for HER2-positive and $ 224,955 for negative tumors, respectively. HER-2 positive cancers are amenable to treatment with targeted biological agents such as trastuzumab. These biological agents are very effective but also very expensive. Thus, they are combined with chemotherapy to make them effective at killing cancer cells.

Lack of awareness to hamper the market growth

Another factor which is hampering the growth of the global HER-2 negative breast cancer market is the lack of awareness among people about HER-2 negative breast cancer. Because of the various difficulties in the diagnosis and treatment of HER-2 negative breast cancer, there is a greater lack of awareness among individuals concerning HER-2 cancer, which has an impact on treatment and diagnosis. Moreover, people in developing & underdeveloped countries have less awareness about HER-2 negative cancer due to a lack of proper healthcare facilities.